Procore signs multi-year strategic collaboration agreement with AWS
On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $27.00 price target for Evolus shares (NASDAQ:EOLS), representing significant upside from the current price of $14.35. According to InvestingPro data, two analysts have recently revised their earnings expectations upward, with price targets ranging from $20 to $27. Following the company’s earnings release, analyst Douglas Tsao provided insight into the performance and expectations for the aesthetic medicine company. Evolus reported a global net revenue of $79 million in the fourth quarter and a total of $266 million for the full year 2024, marking year-over-year growth of 30% and 32%, respectively. These figures align with the preliminary results announced in January. InvestingPro data shows the company maintains a healthy gross profit margin of nearly 70% and operates with a moderate debt level, while its current ratio of 2.47 indicates strong short-term liquidity.
The company also confirmed its 2025 revenue guidance, projecting $345-$355 million, which would represent a 30%-33% increase from the 2024 figures. A key driver of this growth is anticipated to be the newly launched Evolysse product, which is expected to account for 8-10% of the total revenue for the fiscal year 2025. The early approval of Evolysse has bolstered confidence in the company’s ability to meet its projected numbers for the coming year.
Evolus’s strong sales performance in the fourth quarter was a contributing factor to the company achieving full-year profitability ahead of schedule. The positive non-GAAP operating income of $0.3 million for 2024 was a significant milestone, as it was reached a year earlier than anticipated.
In his commentary, Tsao highlighted the incremental details shared about the Evolysse launch and its early approval as a positive development. The analyst’s reiterated Buy rating and price target reflect a continued optimistic outlook for Evolus’s financial trajectory and market performance. With a market capitalization of $909 million and a strong YTD return of 30%, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Evolus Inc . announced its fourth-quarter 2024 financial results, revealing a mixed performance. The company reported an earnings per share (EPS) of -$0.11, which missed the forecasted $0.02. However, Evolus exceeded revenue expectations by reporting $79 million, surpassing the anticipated $76.96 million. Despite the EPS miss, the company achieved full-year profitability ahead of schedule, with a 30% year-over-year increase in global net revenue for the fourth quarter and a 32% rise in full-year net revenues.
Evolus also shared its outlook for 2025, projecting total net revenue between $345 million and $355 million, with newly FDA-approved Evolise products expected to contribute significantly. The company aims for $700 million in revenue by 2028. In terms of market dynamics, Evolus’ market share in the U.S. aesthetic toxin category is expanding, supported by strong U.S. product sales, which accounted for 95% of total revenues.
Additionally, Evolus is set to launch Evolise Form and Evolise Smooth injectable gels, marking a significant milestone in its product portfolio. The company has already begun preparations for this launch, with plans to prioritize training and education for its existing customer base. Despite the challenges in the market, Evolus remains confident in its growth trajectory and strategic initiatives for the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.